StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the medical technology company’s stock.
BIOLASE Trading Up 11.3 %
NASDAQ BIOL opened at $0.01 on Tuesday. The firm’s fifty day simple moving average is $0.01 and its two-hundred day simple moving average is $0.02. BIOLASE has a 12-month low of $0.02 and a 12-month high of $1.94. The firm has a market capitalization of $297,322.30, a P/E ratio of 0.00 and a beta of 0.67.
BIOLASE Company Profile
Featured Articles
- Five stocks we like better than BIOLASE
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- What is a Dividend King?Â
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.